Prime Medicine, Inc.
Financials
Valuation Metrics
Prime Medicine, Inc.'s Market Cap is $800M. At end of 2025 it was $516M. Ranked #2452 of 3,116 in US market (top 79%), #1004 of 1,472 on NASDAQ (top 68%), #181 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $800M | US#2,452/3,116 Sec#181/265 |
| Revenue | $4M | US#2,825/3,116 Sec#179/265 |
| Net Income | $-188M | US—/3,116 Sec—/265 |
| Total Assets | $249M | US#2,941/3,116 Sec#228/265 |
| Net Assets | $40M | US#2,862/3,116 Sec#225/265 |
| Employees | 146 | US#2,539/3,116 Sec#145/265 |
| Value | ||
| P/B | 20.10x | US#2,808/3,116 Sec#221/265 |
| P/S | 196.45x | US#2,958/3,116 Sec#185/265 |
| FCF Yield | -19.60% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -75.45% | US#3,034/3,116 Sec#244/265 |
| Op. Margin | -4824.94% | US#2,831/3,116 Sec#177/265 |
| Revenue Growth | -17.90% | US#2,626/3,116 Sec#148/265 |
| Financial Health | ||
| Debt Ratio | 525.59% | US#2,367/3,116 Sec#222/265 |
| Total Debt | $112M | US#2,396/3,116 Sec#114/265 |
| FCF | $-157M | US#2,728/3,116 Sec#184/265 |
| Cash | $47M | US#2,591/3,116 Sec#228/265 |
| Current Ratio | 3.05x | US#758/3,116 Sec#187/265 |
| Performance | ||
| 1Y Return | -10.32% | US#1,325/3,116 Sec#120/265 |
| 1M Return | 48.66% | US#9/3,116 Sec#3/265 |
| From 52W High | -33.38% | US#1,591/3,116 Sec#90/265 |
| 1Y MDD | -57.61% | US#2,676/3,116 Sec#199/265 |
| Trading | ||
| Volume | 3,852,924 shares | US#151/3,116 Sec#8/265 |
| Trading Value | $17M | US#1,222/3,116 Sec#81/265 |
| Per Share | ||
| EPS | $-1.04 | US—/3,116 Sec—/265 |
| BPS | $0.22 | US#2,778/3,116 Sec#226/265 |
Company Info
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.